AstraZeneca PLC (AZNCF)
| Market Cap | 206.58B |
| Revenue (ttm) | 51.21B |
| Net Income (ttm) | 6.50B |
| Shares Out | n/a |
| EPS (ttm) | 4.15 |
| PE Ratio | 31.81 |
| Forward PE | n/a |
| Dividend | 1.00 (0.80%) |
| Ex-Dividend Date | Aug 8, 2024 |
| Volume | 2,100 |
| Open | 136.79 |
| Previous Close | 135.62 |
| Day's Range | 132.50 - 137.62 |
| 52-Week Range | 118.16 - 175.00 |
| Beta | 0.17 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2024 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]
Financial Performance
In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.
Financial StatementsNews
Levi & Korsinsky Investigates Possible Securities Fraud Violations by AstraZeneca PLC (AZN)
NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violat...
The Law Offices of Frank R. Cruz Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) on behalf of investors concerning the Compan...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN). Such investors are advised to c...
Investors who lost money on AstraZeneca PLC should contact Levi & Korsinsky about an ongoing investigation - AZN
NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violat...
Kuwait: Ali Abdulwahab Al Mutawa Commercial Company and AstraZeneca partnership
This partnership sets out a shared commitment to advancing healthcare in Kuwait via the provision of innovative treatments for conditions such as cardiovascular disease, diabetes, and a range of rare ...
Lightning Round: Take a pass on AstraZeneca, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stock including: Lockheed Martin, UPS, Omeros, Archer Aviation, and AstraZeneca.
An Investigation Has Commenced on Behalf of AstraZeneca PLC Shareholders. Contact Levi & Korsinsky to Discuss your AZN Losses.
NEW YORK, NY / ACCESSWIRE / December 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violat...
AZN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by AstraZeneca PLC
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible viola...
AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe
AstraZeneca's cancer drug Enhertu added to China's reimbursement list, despite ongoing probe into executive.
AstraZeneca's Enhertu included in China's state insurance reimbursement
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an update from the National Healthcare Security Administration.
AstraZeneca’s Enhertu Wins China Reimbursement Despite Probe
China approved AstraZeneca Plc’s blockbuster breast cancer treatment for reimbursement by state-run medical insurance, a move that will boost the British drugmaker’s sales in the country in the midst ...
AstraZeneca asthma drug more effective during attack than steroids, study finds
AstraZeneca's Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that has been the standard of care for 50 years, cutting the need for further t...
AZN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your AstraZeneca PLC investment
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible viola...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are a...
Failure of AstraZeneca Trial Big Blow For Anti-Addiction Drugs: Report
The failure of the trial of the drug AZD4041 by pharma giant AstraZeneca, to combat opioid use disorder (OUD), highlights the challenges in developing non-opioid medications that treat addiction and w...
Shareholder Rights Advocates at Levi & Korsinsky Investigate AstraZeneca PLC (AZN) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible viola...
AstraZeneca PLC Being Investigated on Behalf of AstraZeneca PLC Investors Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible viola...
AstraZeneca reports positive Phase 3 results for Truqap in prostate cancer
AstraZeneca (AZN) reported positive results from a Phase 3 study of its drug Truqap in the treatment of a certain type of prostate cancer. Read more here.
AstraZeneca PLC (AZN) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible viola...
Emergent's Vaccine Production Failure: Contamination Scandal, Investor Backlash, and $40M Settlement
On June 1, 2020, Emergent announced a $628 million contract with the U.S. government to produce COVID-19 vaccines. The company started producing vaccine materials for Johnson & Johnson and AstraZeneca...
Lost Money on AstraZeneca PLC (AZN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible viola...
An Investigation Has Commenced on Behalf of AstraZeneca PLC Shareholders. Contact Levi & Korsinsky to Discuss Your AZN Losses
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible viola...
AstraZeneca (AZN) and Amgen (AMGN) Submit New Asthma Drug Application
AstraZeneca (AZN) and Amgen (AMGN) Submit New Asthma Drug Application
AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns
On Thursday, the Cellular, Tissue, and Gene Therapies Advisory Committee will discuss AstraZeneca Plc’s (NASDAQ: AZN) supplemental biologics license application for Andexxa (coagulation factor Xa (re...
AstraZeneca PLC (AZN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible viola...